Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Study Summary

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.

Conditions

PDAC PDAC - Pancreatic Ductal Adenocarcinoma NSCLC RAS Mutation MTAP Deletion Lung Cancer Pancreatic Cancer Metastatic Thoracic Cancer

Interventions / Drugs

TNG462 RMC-9805 RMC-6236 mFOLFIRINOX gemcitabine/nab-paclitaxel

View on ClinicalTrials.gov ↗

Sponsor

TNGX

Tango Therapeutics, Inc.

Biotech / Pharma

D40/100

Study Details

Enrollment183 participants

Primary Completion—

Lead SponsorTango Therapeutics, Inc.

Data Retrieved2026-04-11 04:29:38.262349+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.